Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma

J. D. Bitran, R. K. Desser, T. R. DeMeester, M. Colman, R. Evans, A. Billings, M. Griem, L. Rubenstein, C. Shapiro, H. M. Golomb

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.

Original languageEnglish (US)
Pages (from-to)1225-1230
Number of pages6
JournalCancer Treatment Reports
Volume60
Issue number9
StatePublished - Dec 1 1976

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Bitran, J. D., Desser, R. K., DeMeester, T. R., Colman, M., Evans, R., Billings, A., Griem, M., Rubenstein, L., Shapiro, C., & Golomb, H. M. (1976). Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma. Cancer Treatment Reports, 60(9), 1225-1230.